ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Company profile
Ticker
OCGN
Exchange
Website
CEO
Shankar Musunuri
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HISTOGENICS CORP
SEC CIK
Corporate docs
Subsidiaries
Ocugen Limited • Ocugen OpCo, Inc. • Histogenics Securities Corporation • Vaccigen Ltd. ...
OCGN stock data
Latest filings (excl ownership)
S-3
Shelf registration
17 Apr 24
10-K
2023 FY
Annual report
16 Apr 24
8-K
Other Events
8 Apr 24
8-K
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
2 Apr 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
1 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Regulation FD Disclosure
21 Mar 24
8-K
Departure of Directors or Certain Officers
20 Mar 24
8-K
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
18 Mar 24
8-K
Regulation FD Disclosure
21 Feb 24
Transcripts
OCGN
Earnings call transcript
2023 Q4
2 Apr 24
OCGN
Earnings call transcript
2023 Q3
9 Nov 23
OCGN
Earnings call transcript
2023 Q2
22 Aug 23
OCGN
Earnings call transcript
2023 Q1
5 May 23
OCGN
Earnings call transcript
2022 Q4
27 Feb 23
OCGN
Earnings call transcript
2022 Q3
8 Nov 22
OCGN
Earnings call transcript
2022 Q2
5 Aug 22
OCGN
Earnings call transcript
2022 Q1
7 May 22
OCGN
Earnings call transcript
2021 Q4
25 Feb 22
OCGN
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 53.48 mm | 53.48 mm | 53.48 mm | 53.48 mm | 53.48 mm | 53.48 mm |
Cash burn (monthly) | 5.70 mm | 4.01 mm | 5.14 mm | 6.75 mm | 4.57 mm | 5.64 mm |
Cash used (since last report) | 38.90 mm | 27.37 mm | 35.09 mm | 46.10 mm | 31.18 mm | 38.48 mm |
Cash remaining | 14.57 mm | 26.11 mm | 18.39 mm | 7.38 mm | 22.30 mm | 14.99 mm |
Runway (months of cash) | 2.6 | 6.5 | 3.6 | 1.1 | 4.9 | 2.7 |
Institutional ownership, Q3 2023
12.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 79 |
Opened positions | 8 |
Closed positions | 21 |
Increased positions | 20 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 13.10 bn |
Total shares | 32.91 mm |
Total puts | 159.00 k |
Total calls | 550.30 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 11.93 mm | $4.77 bn |
GMT Capital | 3.92 mm | $1.57 bn |
BLK Blackrock | 3.69 mm | $1.48 bn |
Geode Capital Management | 2.86 mm | $1.14 bn |
Luminus Management | 2.72 mm | $1.09 bn |
Millennium Management | 1.62 mm | $649.73 mm |
Renaissance Technologies | 921.15 k | $368.50 mm |
STT State Street | 881.63 k | $352.65 mm |
NTRS Northern Trust | 444.95 k | $177.98 mm |
Susquehanna International | 424.80 k | $169.92 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | Huma Qamar | Option Common Stock | Grant | Acquire A | No | No | 1.59 | 308,465 | 490.46 k | 308,465 |
3 Jan 24 | Musunuri Shankar | Common Stock | Payment of exercise | Dispose F | No | No | 0.653 | 180,204 | 117.67 k | 2,009,869 |
3 Jan 24 | Arun Upadhyay | Common Stock | Payment of exercise | Dispose F | No | No | 0.653 | 41,633 | 27.19 k | 349,589 |
2 Jan 24 | Musunuri Shankar | Option Common Stock | Grant | Acquire A | No | No | 0.6576 | 492,126 | 323.62 k | 492,126 |
News
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
22 Apr 24
Ocugen Says It Has Completed Dosing of Subjects With Geographic Atrophy In Cohort 2 Of Phase 1/2 ArMaDa Clinical Trial Of OCU410—A Modifier Gene Therapy
19 Apr 24
Why Ocugen Shares Are Trading Higher
8 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 Apr 24
Ocugen Reveals US FDA Clearance Of IND Amendment To Begin OCU400 Phase 3 Clinical Trial - First Gene Therapy To Enter Phase 3 With Broad Retinitis Pigmentosa Indication
8 Apr 24
Press releases
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, QuidelOrtho, and Sharecare and Encourages Investors to Contact the Firm
23 Apr 24
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
23 Apr 24
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
23 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
20 Apr 24
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, and QuidelOrtho and Encourages Investors to Contact the Firm
19 Apr 24